PSS33 - SECUKINUMAB AS FIRST BIOLOGIC TREATMENT- A COST PER RESPONDER ANALYSIS COMPARED WITH LICENSED BIOLOGICS, FOR MODERATE TO SEVERE PSORIASIS IN ARGENTINA
Oct 1, 2018, 00:00 AM
10.1016/j.jval.2018.09.2533
https://www.valueinhealthjournal.com/article/S1098-3015(18)35835-2/fulltext
Section Title :
Section Order :
1887
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35835-2&doi=10.1016/j.jval.2018.09.2533